Innovative Medicine
-
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic -
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
· Application is based on positive data from the Phase 3 CANDOR study, which were presented at the 2019 American Society of Hematology Annual Meeting -
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA® (apalutamide), niraparib and BALVERSATM (erdafitinib) -
Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India
Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer -
Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
In two pivotal Phase 3 trials, SPRAVATO®▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ideation with intent compared to comprehensive standard of care alone -
-
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone · Data selected as a Late-Breaking Abstract at ASH 2019 -
Janssen to Acquire Investigational Bermekimab from XBiotech
Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa -
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma
Newest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myeloma Initial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting